Organization
Pierre Fabre Medicament
11 clinical trials
1 abstract
Clinical trial
A Multicenter, Randomized, Open-label, 2-arm, Phase II Study With a Safety lead-in Phase Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.Status: Active (not recruiting), Estimated PCD: 2023-12-19
Clinical trial
Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal CancerStatus: Completed, Estimated PCD: 2020-06-29
Clinical trial
Phase I Dose Escalation and Dose Expansion, International, Multicenter Study of W0180 as Single Agent and in Combination With Pembrolizumab (Anti-PD-1) in Adult Participants With Locally Advanced or Metastatic Solid TumorsStatus: Terminated, Estimated PCD: 2023-12-19
Clinical trial
Randomised Phase II Study of the Combination of Oral Vinorelbine With Capecitabine Versus Gemcitabine in Combination With Paclitaxel Versus Gemcitabine in Combination With Docetaxel as First Line Chemotherapy in Patients With Metastatic Breast CancerStatus: Completed, Estimated PCD: 2013-04-18
Clinical trial
Multicenter, Open-label, Phase II Study With a Safety Lead-in Part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer Who Are BRAF- and MEK Inhibitor Treatment-naïveStatus: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical TrialStatus: Completed, Estimated PCD: 2022-01-31
Clinical trial
'An Open Label, Multicentre, Phase I Study to Evaluate the Impact of Moderate and Severe Hepatic Impairments on the Pharmacokinetics and Safety of Encorafenib in Combination With Binimetinib in Adult Patients With Unresectable or Metastatic BRAF V600-mutant Solid Tumors'.Status: Withdrawn, Estimated PCD: 2023-05-01
Clinical trial
A Randomized, Single-center, Open-label, Single Dose, Two-period, Crossover Pivotal Bioequivalence Study Comparing Binimetinib 3 x 15 mg and 45 mg Tablets in Healthy ParticipantsStatus: Completed, Estimated PCD: 2022-12-22
Clinical trial
Phase I/II Open Label Dose Escalation and Dose Expansion Study of Intravenous Infusion of W0101, an Antibody-drug Conjugate, in Patients With Advanced or Metastatic Solid Tumors. International, Multicenter, Open Label StudyStatus: Active (not recruiting), Estimated PCD: 2021-10-30
Clinical trial
Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma GroupStatus: Active (not recruiting), Estimated PCD: 2027-03-31
Abstract
Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design.Org: Melanoma Institute Australia, University Hospital (UKSH), Campus Kiel, Department of Dermatology, Kiel, Germany, University of Perugia, Ospedale Santa Maria della Misericordia, European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, European Organization for Research and Treatment of Cancer (EORTC), Headquarters,
Clinical trial
Multicenter, Open-label, Phase 1 Study Investigating the Safety and Tolerability of Encorafenib Monotherapy in BRAF V600E-mutated Chinese Patients With Advanced Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2022-05-06